Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

RECRUITING

Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy

Lead Sponsor:

RAPT Therapeutics, Inc.

Conditions:

Ig-E Mediated Food Allergy

Eligibility:

All Genders

12-55 years

Phase:

PHASE2

Brief Summary

Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy: This is a Phase 2b randomized, double-blind, placebo-controlled clinical trial evaluating RPT904, a next-generat...

Detailed Description

Phase 2b Randomized, Double-Blind, Placebo-Controlled Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy

Eligibility Criteria

Inclusion

  • Key
  • Participant and/or parent/legal guardian must be able to understand and provide informed consent and/or assent, as applicable.
  • Male or female, 12 to less than 56 years of age at screening.
  • Allergic to at least 1 of the following foods: peanut, milk, egg, cashew, or walnut, as confirmed by the following criteria:
  • a. For participants aged 12 to \<18 years:
  • i. Allergic to peanut: participant must meet all criteria below:
  • 1\. Positive SPT (≥4 mm wheal greater than saline control) to peanut.
  • 2\. Positive peanut IgE (≥6 kUA/L) at screening or within 3 months of screening.
  • 3\. Positive blinded oral food challenge (OFC) to peanut during the screening DBPCFC, defined as experiencing dose-limiting symptoms at a single dose of ≤100 mg (ie, cumulative dose of ≤144 mg) of peanut protein.
  • ii. Allergic to milk or egg: unable to tolerate both cooked and uncooked forms:
  • 1\. Positive SPT (≥4 mm wheal greater than saline control) to the specific food.
  • 2\. Positive food-specific IgE (≥6 kUA/L) at screening or within 3 months of screening.
  • 3\. Positive blinded OFC to the specific food during the screening DBPCFC, defined as experiencing dose-limiting symptoms at a single dose of ≤300 mg (ie, cumulative dose of ≤444 mg) of food protein.
  • iii. Allergic to cashew: participant must meet all criteria below:
  • 1\. Positive SPT (≥4 mm wheal greater than saline control) to cashew. OR
  • 2\. Positive cashew IgE (≥6 kUA/L) at screening or within 3 months of screening. AND
  • 3\. Positive blinded OFC to cashew during the screening DBPCFC, defined as experiencing dose-limiting symptoms at a single dose of ≤100 mg (ie, cumulative dose of ≤144 mg) of cashew protein.
  • iv. Allergic to walnut: participant must meet all criteria below:
  • 1\. Positive SPT (≥4 mm wheal greater than saline control) to walnut. OR
  • 2\. Positive walnut IgE (≥6 kUA/L) at screening or within 3 months of screening AND
  • 3\. Positive blinded OFC to walnut during the screening DBPCFC, defined as experiencing dose-limiting symptoms at a single dose of ≤300 mg (ie, cumulative dose of ≤444 mg) of walnut protein.
  • b. For participants aged 18 to \<56 years:
  • i. Allergic to peanut or cashew: participant must meet all of the following criteria:
  • 1\. Positive SPT (≥3 mm wheal greater than saline control) to peanut or cashew.
  • 2\. Positive peanut or cashew IgE (≥0.35 kUA/L) at screening or within 3 months of screening.
  • 3\. Positive blinded OFC to peanut or cashew during the screening DBPCFC, defined as experiencing dose-limiting symptoms at a single dose of ≤100 mg (ie, cumulative dose of ≤144 mg) of peanut or cashew protein.
  • ii. Allergic to milk or egg: participant must meet all of the following criteria:
  • 1\. Positive SPT (≥3 mm wheal greater than saline control) to the specific food.
  • 2\. Positive food-specific IgE (≥0.35 kUA/L) at screening or within 3 months of screening.
  • 3\. Positive blinded OFC to the specific food during the screening DBPCFC, defined as experiencing dose-limiting symptoms at a single dose of ≤300 mg (ie, cumulative dose of ≤444 mg) of food protein.
  • iii. Allergic to walnut: participant must meet all of the following criteria:
  • 1\. Positive SPT (≥3 mm wheal greater than saline control) to walnut.
  • 2\. Positive walnut IgE (≥0.35 kUA/L) at screening or within 3 months of screening.
  • 3\. Positive blinded OFC to walnut during the screening DBPCFC, defined as experiencing dose-limiting symptoms at a single dose of ≤300 mg (ie cumulative dose of ≤444 mg) of walnut protein.
  • With body weight (as measured at screening) and total serum IgE level (as measured within 3 months of screening) suitable for RPT904 dosing (per RPT904 dosing table).
  • Female Participants:
  • 1\. Must not be pregnant or breastfeeding.
  • 2\. Women of non-childbearing potential (e.g., surgically sterile or postmenopausal) are eligible.
  • 3\. Women of childbearing potential must have a negative pregnancy test before starting study treatment, agree to use a protocol-defined method of contraception during the study and for at least 16 months after the last dose, and must not donate eggs or undergo egg retrieval during this period.
  • Male Participants:
  • 1\. Must agree to either remain abstinent from heterosexual intercourse (if that is their usual lifestyle) or use protocol-defined contraception during the study and for 16 months after the last dose.
  • 2\. Must not donate semen or participate in sperm banking during this time, and if they have a female partner of childbearing potential, she should also use effective contraception.

Exclusion

  • Clinically significant lab abnormalities at screening.
  • Sensitivity or suspected/known allergy to any component of the active or placebo OFC material (excluding the test allergens peanut, milk, egg, walnut, and cashew being tested), or drugs related to RPT904 (eg, monoclonal antibodies, polyclonal gamma globulin).
  • Uncontrolled or severe asthma/wheezing at screening.
  • Current use of oral, IM, or IV corticosteroids, tricyclic antidepressants, or β-blockers (oral or topical).
  • Past or current immunotherapy to any study foods within 6 months of screening.
  • Treatment with immunomodulatory therapy within 6 months of screening.
  • Currently in the "build-up phase" of inhalant allergen immunotherapy (i.e., not yet on maintenance). Note: individuals on stable maintenance dosing may be eligible.
  • Past or current medical problems (eg, severe latex allergy), chronic diseases (other than asthma/wheezing, atopic dermatitis, or rhinitis) requiring therapy (eg, heart disease, diabetes), abnormal physical findings or lab results not listed above that, in the Principal Investigator's opinion, may increase study related risks, hinder protocol compliance, or impact data quality or interpretation .

Key Trial Info

Start Date :

October 22 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

January 1 2028

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT07220811

Start Date

October 22 2025

End Date

January 1 2028

Last Update

December 29 2025

Active Locations (8)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (8 locations)

1

Arkansas Children's

Little Rock, Arkansas, United States, 72202

2

Asthma & Allergy Associates, P.C.

Colorado Springs, Colorado, United States, 80907

3

Children's Healthcare of Atlanta - Center for Advanced Pediatrics

Atlanta, Georgia, United States, 30329

4

Clinical Research Institute, Inc

Minneapolis, Minnesota, United States, 55402